Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fosun International ( (HK:0656) ) has shared an update.
Fosun Pharma has announced the first grant under its 2025 H Share RSU Scheme, reducing the number of grantees to 195 and the RSUs to 10,589,500 due to changes in eligible employees. This move is part of its strategic efforts to incentivize employees and align their interests with the company’s growth, reflecting Fosun Pharma’s ongoing commitment to enhancing shareholder value and operational efficiency.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
More about Fosun International
Fosun International is a diversified conglomerate with interests in various industries, including pharmaceuticals, where it operates through its subsidiary Fosun Pharma. The company focuses on developing and distributing healthcare products and services, aiming to strengthen its market position in the pharmaceutical sector.
Average Trading Volume: 14,689,763
Technical Sentiment Signal: Hold
Current Market Cap: HK$40B
For a thorough assessment of 0656 stock, go to TipRanks’ Stock Analysis page.